SCHEMBL3046549

SCHEMBL3046549

O=c1ccc2ccccc2n1-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.53
BRD4 O60885 1/20 0.53
BRPF1 P55201 1/20 0.53
CA9 Q16790 1/20 0.53
KAT2B Q92831 1/20 0.53
BRD9 Q9H8M2 1/20 0.53
ALDH1A1 P00352 2/20 0.50
TSHR P16473 2/20 0.50
KDM4E B2RXH2 1/20 0.45
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
GSK3A P49840 3/20 0.43
GSK3B P49841 3/20 0.43
GAA P10253 1/20 0.43
CDK4 P11802 1/20 0.43
CCND1 P24385 1/20 0.43
CCND2 P30279 1/20 0.43
CCND3 P30281 1/20 0.43
MAPK1 P28482 2/20 0.42
PGR P06401 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29941621 1.00 CA12 (0.53) CA12BRD4BRPF1CA9KAT2B
SCHEMBL28409273 0.98 CA12 (0.52) CA12BRD4BRPF1CA9KAT2B
SCHEMBL28412720 0.98 CA12 (0.52) CA12BRD4BRPF1CA9KAT2B
SCHEMBL8040091 0.85 CA12 (0.52) CA12BRD4BRPF1CA9KAT2B
SCHEMBL7293263 0.85 BRPF1 (0.47) CA12BRD4BRPF1CA9KAT2B
SCHEMBL11693860 0.81 LMNA (0.53) CA12BRD4BRPF1CA9KAT2B
SCHEMBL7286251 0.79 SCN2A (0.47) CA12BRD4BRPF1CA9KAT2B
SCHEMBL17505192 0.78 BRPF1 (0.56) BRPF1ALDH1A1TSHRKDM4EL3MBTL1
SCHEMBL9159347 0.78 ALDH1A1 (0.46) ALDH1A1TSHRKDM4EGAAMAPK1
SCHEMBL140196 0.78 ALDH1A1 (0.42) ALDH1A1TSHRL3MBTL1GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102675200-A 2-phenyl-4-carbostyril compounds with antineoplastic activity, and preparation method and usage thereof UNIV CHINA PHARMA 2012-09-19 CN claimed
CN-1382124-A Bicyclic androgen and progesterone receptor modulating compounds and methods LIGAND PHARM INC (US) 2002-11-27 CN claimed
US-4420308-A Process for the production of reserve effects on polyester textiles and polyester/cellulose mixed fibre textiles: discharge printing with disperse azo dye with alkyl or alkoxy carbonyl, cyand and hydroxy phenyl group CASSELLA AKTIENGESELLSCHAFT (DE) 1983-12-13 US claimed
WO-2024080788-A1 NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF 한미약품 주식회사 2024-04-18 WO disclosed
US-20100158905-A1 COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST NUON THERAPEUTICS, INC. (US) 2010-06-24 US disclosed
EP-1273971-B1 Process for photopolymerization by exposure of a photosensitive lithographic printing plate FUJIFILM CORP (JP) 2010-02-10 EP disclosed
EP-1981341-A2 INHIBITORS OF FATTY ACID SYNTHASE (FAS) Merck and Co., Inc. (US) 2008-10-22 EP disclosed
CN-100384823-C Bicyclic androgen and progesterone receptor modulator compounds and methods LIGAND PHARM INC (US) 2008-04-30 CN disclosed
CN-101029042-A Bicyclic androgen and progesterone receptor modulator compounds and methods LIGAND PHARM INC (US) 2007-09-05 CN disclosed
WO-2007089634-A2 INHIBITORS OF FATTY ACID SYNTHASE (FAS) MERCK & CO., INC. (US) 2007-08-09 WO disclosed
US-20070148185-A1 Novel therapeutic target for protozoal diseases VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY 2007-06-28 US disclosed
CN-1775759-A Bicyclic androgen and progesterone receptor modulator compounds and methods LIGAND PHARM INC (US) 2006-05-24 CN disclosed
CN-1382124-A Bicyclic androgen and progesterone receptor modulating compounds and methods LIGAND PHARM INC (US) 2002-11-27 CN disclosed
US-5436134-A Fluorescent dyes for nucleic acids MOLECULAR PROBES, INC. (US) 1995-07-25 US disclosed
WO-1995003300-A1 HETEROARYL QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS MERCK FROSST CANADA INC. (CA) 1995-02-02 WO disclosed
US-4420308-A Process for the production of reserve effects on polyester textiles and polyester/cellulose mixed fibre textiles: discharge printing with disperse azo dye with alkyl or alkoxy carbonyl, cyand and hydroxy phenyl group CASSELLA AKTIENGESELLSCHAFT (DE) 1983-12-13 US disclosed
US-4365018-A SELF-EXPOSING, CHEMILUMINESCENCE THE MEAD CORPORATION (US) 1982-12-21 US disclosed
US-4058532-A 1-Phenyl-3,4-dihydrocarbostyrils STERLING DRUG INC. (US) 1977-11-15 US disclosed
US-4049715-A 3-[2-(4-Anisidino)phenyl]-1-phenyl-1-propiophenones and propanols STERLING DRUG INC. (US) 1977-09-20 US disclosed
US-3994902-A Certain 1,2-diphenyl-1,2,3,4-tetrahydroquinoline compounds STERLING DRUG INC. (US) 1976-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158905-A1 COMBINATION THERAPY OF ARTHRITIS WITH TRANILAST PTGS2, PTGES2, PTGES CA12 3817/4885BRD4 654/4885BRPF1 1240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.